Oncorus, Inc. announced it will present initial data from its ongoing Phase 1 clinical trial of ONCR-177 at the upcoming Society for Immunotherapy of Cancer’s 36th Annual Meeting, taking place November 12–14, 2021 in Washington, D.C. and virtually. ONCR-177, Oncorus’ lead oncolytic Herpes Simplex Virus product candidate, is an intratumorally administered viral immunotherapy being developed for multiple solid tumor indications. The Phase 1 open-label, multi-center, dose escalation and expansion clinical trial is designed to evaluate the safety and tolerability of ONCR-177 alone and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors or with liver metastases of solid tumors. The details for Oncorus’ SITC poster are as follows: Title: Initial results of a Phase 1 study of intratumoral ONCR-177, an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes, in subjects with advanced injectable tumors. Abstract #: 511 Primary Author/Presenter: Jong Chul Park, M.D., Instructor, Medicine, Harvard Medical School and Assistant, Medicine, Massachusetts General Hospital. Date/Time: November 12–14, 2021, 7:00 a.m.– 8:30 p.m. ET Location: Poster Hall, Walter E. Washington Convention Center, Washington, D.C.